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Summary 
The EVA structural descriptor, based upon calculated fundamental molecular vibrational 
frequencies, has proved to be an effective descriptor for both QSAR and database similarity 
calculations. The descriptor is sensitive to 3D structure but has an advantage over field-
based 3D-QSAR methods inasmuch as structural superposition is not required. The original 
technique involves a standardisation method wherein uniform Gaussians of fixed standard 
deviation (σ) are used to smear out frequencies projected onto a linear scale. This smearing 
function permits the overlap of proximal frequencies and thence the extraction of a fixed 
dimensional descriptor regardless of the number and precise values of the frequencies. It is 
proposed here that there exist optimal localised values of σ in different spectral regions; that 
is, the overlap of frequencies using uniform Gaussians may, at certain points in the 
spectrum, either be insufficient to pick up relationships where they exist or mix up 
information to such an extent that significant correlations are obscured by noise. A genetic 
algorithm is used to search for optimal localised σ values using crossvalidated PLS 
regression scores as the fitness score to be optimised. The resultant models are then 
validated against a previously unseen test set of compounds. The performance of EVA_GA 
is compared to that of EVA and analogous CoMFA studies. 
Introduction 
EVA is a molecular descriptor that is derived from calculated fundamental infra-red (IR) 
and Raman range vibrational frequencies [1,2,3]. The descriptor has the advantage over 
popular 3D-QSAR methods such as CoMFA [4] in as much as it is invariant to rotation and 
translation of the structures concerned and it is therefore not necessary to superpose 
compounds in order to provide descriptors. Extensive studies [2,3] have indicated that EVA 
can successfully be used to develop QSAR models for a range of different structural classes, 
exhibiting various degrees of conformational freedom and with a variety of biological 
endpoints. These studies also found that EVA, like field-based 3D-QSAR, can perform well 
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with heterogeneous sets of structures. In most cases the EVA models were found to be 
statistically entirely comparable to those obtained using CoMFA but without the difficulties 
associated with structural superposition. A detailed study with a benchmark steroid dataset 
[3] indicated that EVA can provide statistically robust QSAR models when this is judged by 
the scores from internal crossvalidation, random permutation tests and external test set 
prediction. 
This paper describes a modification to the way in which the EVA descriptor is calculated 
that has been developed with a view to providing QSAR models with enhanced internal and 
external predictivity. The "classical" EVA descriptor (henceforth referred to as EVA) is 
derived by projecting normal mode frequencies (NMFs) onto a linear scale and then 
smearing them out using Gaussian kernels such that proximal frequencies are permitted to 
overlap. A fixed-dimensional standardised descriptor is then extracted for any chosen 
molecule, as described in more detail below. Previously, for a given analysis, EVA has been 
extracted using Gaussian kernels of fixed standard deviation (σ) across the spectrum. This is 
necessary because it means that each frequency (i.e., each part of the spectrum) is equally 
weighted prior to regression analysis. It has been found that the quality of the QSAR model 
very often is dependent upon the chosen σ and that the best σ to use can vary substantially 
[2,3]. The general approach [3] has been to generate many sets of EVA descriptors based 
upon a variety of σ and, on the basis of training set crossvalidation results, select a σ 
expansion term that is expected to provide an optimally predictive model for a previously 
unseen test set. The effectiveness of this model-selection method has been clearly 
demonstrated with a steroid dataset [3].  
In the work described herein σ has been permitted to have localised values at different 
regions on the linear scale. This approach should permit the determination of an optimal or 
near-optimal overlap of kernels across the spectrum, where the quality of this overlap is 
judged by the scores from subsequent PLS regression using the derived descriptor matrix. 
The basis of this study is the postulate that there exist localised values of σ associated with 
different regions of the spectrum that provide improved internal and external predictivity 
relative to those obtained with any model based on a fixed σ term. At the same time there is 
a requirement to search for an optimal set of these σ values and, for reasons explained 
below, a genetic algorithm (GA) has been used to direct this search. PLS [5] crossvalidation 
regression scores are used as the fitness function to be optimised by the GA. The proposed 
technique is fundamentally different from more standard variable selection techniques [6-8] 
in as much as variables are not included/excluded by the procedure; rather, it is their 
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information content (i.e., the selection of frequencies contributing to a variable) that is 
altered through the adjustment of kernel overlap. 
An incentive for the development of this new approach to EVA, referred to hereafter as 
EVA_GA, is that there are a number of datasets with which EVA has previously not 
performed well [2], either in absolute terms or relative to CoMFA – the reasons for this 
under-performance are not apparent. In addition to the potential for providing improved 
QSAR predictions, it may be the case that the use of localised σ improves the possibilities 
for interpretation of an EVA QSAR model (i.e., back-tracking to structure). 
Methods 
Notation 
The following is an alphabetic list of abbreviations related to PLS analyses: A − number of 
PLS LVs; CV − crossvalidation; F − Fischer significance score; G − number of CV groups; 
LOO − leave-one-out CV (G = M); LNO − leave-n-out CV, where n > 1; LVopt − optimum 
number of latent variables (LVs); M − number of training set molecules; pr2 − test set 
predictive-r2; PRESS − predictive residual sum of squares; q2 − LOO CV r2; r2 − fitted 
model r2; SE and SECV − Standard Error and CV-SE; TG − training set; X − matrix of 
descriptor variables; Y − dependent variable (bioactivity etc.) 
For the EVA descriptor and EVA_GA the following abbreviations are used: BFS − linear 
bounded frequency scale; CONV_CRIT − difference between fitness scores of the least and 
most fit members of a GA population; H − Hamming threshold; LVmax − number of LVs 
evaluated by EVA_GA; MAX_CYCLES − maximum number of GA generations; 
N − number of atoms in a molecule; NBINS − number of bins into which BFS is divided; 
NMF − normal mode frequency; NPOP − number of GA chromosomes; R − set of r σ 
values from which elements of V are selected; V − a GA chromosome; Vopt − an optimal V. 
Software and Hardware 
All the work described herein was carried out using a multiprocessor Silicon Graphics 
Origin 200 R10000. The molecular modelling software used was Sybyl 6.3 [9]. The 
software required to run the GA, to perform the EVA standardisation process and to do the 
GA-related PLS analyses was custom-written in the C programming language. 
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Classical EVA 
The EVA descriptor [1,2] is derived from fundamental molecular vibrational frequencies of 
which there are 3N-6 (or 3N-5 for a linear compound such as acetylene) for an N-atom 
structure. The frequency values are projected onto a linear bounded frequency scale 
covering the range 1 to 4,000 cm-1 and then smeared out, and therefore overlapped, through 
the application of Gaussian kernels to each and every frequency value. Finally, the BFS is 
sampled at fixed intervals of L cm-1. The value of the EVA descriptor at a point, x, on the 
BFS is the sum of amplitudes of the overlapped kernels at that point: 
 EVA
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where fi is the ith normal mode frequency of the compound concerned. 
This process is repeated for each dataset structure, thus providing a descriptor of fixed 
dimension for all compounds. Typically a descriptor set may be derived using a σ of 10 cm-1 
and an L of 5 cm-1 resulting in 800 (4,000/L) descriptor variables [1]. The number of 
variables is thus very much larger than the number of compounds in a standard QSAR 
dataset and the Partial least squares to Latent Structures (PLS) technique [5] has been used 
to provide a robust regression analysis. The purpose of the EVA smoothing procedure is not 
to simulate an experimental IR spectrum (transition dipole data is not used and, therefore, all 
kernels are of fixed maximum amplitude) but rather it is to apply a density function such 
that vibrations at slightly different frequencies in different compounds can be "overlapped" 
and thus compared with one another. The extent of this overlap is governed by σ and the 
proximity of vibrations on the BFS. 
Localising σ 
In classical EVA the kernels have a uniform fixed standard deviation (equal width, height 
and shape) for all frequencies in all compounds while, as stated above, σ is here permitted to 
have localised values in different spectral regions. The local values are to be selected so as 
to improve model predictivity and, as with the selection of a suitable fixed σ value, training 
set CV is used to select an optimal set of localised σ.  
There are a number of ways in which the concept of a localised σ might be applied to EVA-
descriptor generation. It is possible to associate each and every NMF in each and every 
compound of a dataset with its own localised σ value. Such a scheme would, however, only 
be appropriate were there not to be a requirement to make external test predictions, since 
there would be no way of assigning localised σ values for the test set compounds without 
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including them in the optimisation procedure. In addition, the number of adjustable 
parameters would be extremely large (M × (3N-6)) for typical QSAR datasets. It was, 
therefore, decided to divide the BFS into NBINS bins of equal width (w), with each of 
which a localised σ value is associated. The Gaussian kernel for any frequency in any 
structure whose value falls within a given bin (spectral sub-region) is thus expanded using 
the σ associated with that bin. NBINS (4,000/w) is thus independent of both M and the 
number of NMFs (proportional to N). A potential solution is thus a vector, V, consisting of 
NBINS elements: 
 V = { σ1, σ2, σ3, … σNBINS-2, σNBINS-1, σNBINS } 
Each of the NBINS sub-regions cannot be independently evaluated because the information 
content of descriptors located in adjacent bins is generally not independent: except where σ 
is very small indeed, kernels centred in adjacent bins tend to overlap one another thus 
adding additional signal (or noise) to the descriptors concerned. The extent of such overlap 
depends upon the relative frequency values and the local σ applied. Only the main spectral 
sub-regions (the fingerprint / functional group-stretching and hydrogen-stretching) are 
sufficiently far apart on the BFS such that there is no overlap unless σ were to be extremely 
large (Figure 1). 
Without imposing constraints upon the values that local σ can assume the search space is 
huge; e.g., if only integer values in the range 1 to 50 cm-1 were to be permitted then full 
coverage of σ space would require a search of 50NBINS permutations. Therefore, a restriction 
is placed on the values that local σ can assume and are taken from a user-defined r element 
vector (R) where:  
 R = { σi, σii, …, σr-1, σr } 
A suitable set of values for R may, for example, be {5, 10, 15, 20, 40} and a solution V has 
elements taken from R. The use of a representative set of discrete values such as these is 
justified since previous work has shown that for small changes in σ there tends to be little 
difference in the ensuing PLS scores [2,3]. For a particular dataset, R may be selected to 
reflect results obtained when using a range of fixed σ values; i.e., one may wish to bias the 
solution toward previously obtained results. The total number of permutations where r = 5 is 
thus 5NBINS which, where w = 40 cm-1, is equivalent to 5100 (~1070). In practice there are 
substantial regions of the IR spectrum in which there tend to be no NMFs (Figure 1), 
particularly outside the skeletal region (~1,500–4,000 cm-1). This feature means that, for the 
melatonin data set described below, and where w = 40 cm-1, NBINS is reduced from 100 to 
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62. This significantly reduces the available permutations to 562 (~1043) but nonetheless 
remains a large search space. A σ value of zero has not been permitted here since this would 
allow NMFs to be omitted from consideration altogether, although this may form the basis 
of a variable selection procedure. 
A second problem that arises with the use of localised σ values is that, without some form of 
scaling, there will be variance that is related solely to the chosen σ (i.e., kernel maximum 
amplitude differences) rather than to differences in frequency value location on the BFS. 
Therefore, all kernels are scaled to a maximum amplitude of unity prior to determining the 
local EVA descriptor values. This means that the kernels differ only in terms of their width, 
and to a lesser extent, shape (Figure 2) rather than height, shape and width. 
Searching for an Optimal Solution (Vopt)  EVA_GA 
As stated previously the number of possible solutions to be explored is immense and all 
possible permutations of the elements of V cannot be evaluated systematically. Therefore, a 
technique is required that permits a sampling of the search space in as thorough a manner as 
possible without the requirement to cover that space in its entirety. Genetic algorithms 
[10,11] provide an obvious and convenient means to approach the stated problem. GAs are 
now a well-established stochastic technique for performing directed random searches of a 
problem space and have been widely applied to drug design and chemometric problems 
[12]. A wide variety of alternative formulations are available the selection of which are to 
some extent arbitrary; details of the chosen methods are given below while Figure 3 is a 
generalised overall schema for EVA_GA. 
A. Chromosome encoding. In the current context a chromosome conveniently consists of 
the vector, V, described above. In order to ensure the diversity of the initial population a 
Hamming threshold (H) was applied such that at the outset each chromosome was permitted 
to have a maximum of H genes of identical value to those of any other chromosome. The 
minimum possible value of H depends upon NPOP, NBINS and the number of possible 
different values associated with each bin (r). 
B. Chromosome fitness evaluation. The chromosome fitness function is the q2 score from 
PLS CV based upon an EVA descriptor set derived using V; the higher the q2 score the 
greater the chromosome fitness. Both LOO and LNO CV have been implemented  the 
advantages and disadvantages of these two approaches are discussed below. The SAMPLS 
algorithm [13] provides a highly efficient implementation of PLS-1 and, for univariate Y 
only, gives identical results to the classical NIPALS [5] and SIMPLS [14] algorithms. 
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SAMPLS is based upon reduction of the X block data to an M-by-M covariance matrix of 
all the pair wise "distances" between each of M molecular descriptor vectors which is then 
used to fit all PLS LVs independent of the original number of variables. SAMPLS was 
custom-written so as to provide a very efficient implementation and full integration with the 
GA and EVA descriptor code; for example, with M = 21 and 1000 variables LOO CV using 
five LVs required only ~0.01 seconds. 
C. Reproduction. The reproductive stage involves three steps; viz. parent selection, 
crossover and mutation. Parents are selected using the roulette wheel method whereby 
parents are selected in a probabilistic manner in which those with a higher fitness are more 
likely to be selected than those with lower fitness. However, an élitist model [15] also was 
implemented in which the best member of the current parent population is forced to be in 
next generation. Both single and double crossover points are permitted, the selection of 
which is done at random as are the points at which crossover takes place. Mutation is 
permitted at random points on a randomly selected chromosome − a chromosome may be 
selected for mutation (or crossover) more than once − and, while the σ at the mutated point 
is selected at random from R, the new value is forced to be different from the current value. 
Child population duplicates are mutated in the same way. The probability, Pm, of mutation is 
set to 0.05 (although this can be altered by a user)  this is somewhat higher than a typical 
value of 0.01 and was chosen to encourage exploration of the large search space. The 
probability, Pc, of crossover is also user-definable but was fixed at 0.85 herein. 
D. Evaluation of ultimate GA solution(s). The optimal solution(s) provided by the GA is 
(are) evaluated against a previously unseen set of compounds (the test set) where such is 
available. This enables one to test for over-fit to the training set and must be considered a 
crucial model validation procedure where, as here, a large number of adjustable parameters 
(σ) are involved. Training set random permutation tests also are applied to all Vopt and 
estimates made that the observed q2 and r2 scores could be chance effects; 1,000 
permutations of the activity data were made in every case. 
E. PLS model selection strategies. The selection of model-dimensionality (LVopt) and thus 
the fitness score (q2) of a particular chromosome during evolution of the GA requires careful 
consideration. Scoring on the basis of the first q2 maximum (keyword: MAX_Q2) provides 
the most obvious method. However, in the interests of efficiency it is desirable to extract as 
few LVs as possible while at the same time model parsimony is, in general terms, 
considered to be desirable [16] when external predictivity is a criterion. Model parsimony 
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can be favoured by using, for example, a formula for calculating SECV that penalises 
additional LVs [16]: 
  ( )SE PRESS / (M A 1)
CV
1/2= − −
Thus, models can be extracted on the basis of the first SECV-minimum (keyword: 
SECV_MIN). Alternatively, or additionally, a 5% rule (keyword: 5%_RULE) may be 
applied [16] wherein an additional LV is permitted only where it raises q2 by ≥ 0.05 units. In 
general, but not always where M is small, the latter method is at least as parsimonious as the 
SECV_MIN approach. However, the purpose of the GA is to search for better solutions, the 
quality of which are judged by the q2 scores. A "better" solution can be seen as any vector, 
V, that provides a higher q2 than obtained previously. An q2 improvement may be very 
small, and may require an additional LV in comparison to other models with slightly smaller 
q2 but may provide an intermediary model in the progress toward a significantly better 
solution. It is, therefore, arguable as to whether MAX_Q2, SECV_MIN or the 5%_RULE 
should be the model selection criterion and various comparative tests are made using 
otherwise identical EVA_GA runs. 
An upper bound to the value of LVopt is that it should not exceed M/4 since the use of a ratio 
greater than this results in increased probability of chance correlation [17]. Finally, it is not 
acceptable to make predictions of the biological activity of structures to greater precision 
than the error in (reproducibility of) the original measurements. This factor has been directly 
addressed for the steroids [3] while the relevant information is not available for the 
melatonin compounds. 
F. Default EVA_GA parameters. The following set of default GA parameters are defined: 
CONV_CRIT = 0.05 (i.e. there is no significant difference between the fitness scores of the 
most and least fit population members); MAX_CYCLES = 100; NBINS = 100 (i.e., 
w = 40 cm-1); NPOP = 100; PLS_MODEL_SELECTION = 5%_RULE. Crossvalidation can 
be LOO or LNO; unless otherwise stated, in the latter case G = 7 and CV is repeated 50 
times and mean values reported for q2 and SECV. Parameters such as R and LVmax are set 
according to the dataset involved and can be based upon examination of a range of results 
with EVA. 
Datasets 
The performance of EVA_GA was evaluated using datasets for which external test sets were 
available and consist of a benchmark steroid dataset [4,18,19] and a set of melatonin 
receptor ligands [20]. The use of test sets must be considered essential for validating an 
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EVA_GA QSAR model since the large number of adjustable parameters (NBINS) means a 
priori that there is great potential for training set overfit.  
Steroids. The steroid set consists of 21 TG and 10 test set compounds (Table 1), originally 
investigated (in terms of 3D-QSAR analysis) by Cramer et al. [4]. This dataset has been 
described in detail previously together with both CoMFA and EVA analyses [3] and is not 
described further here; the activity data are measured corticosteroid-binding globulin 
affinities expressed as log [K]. The PLS results with EVA were good and it is of interest to 
determine whether or not EVA_GA can enhance this in any way. Whilst this dataset has 
been widely used as a benchmark for novel QSAR methods [18] it completely lacks any sort 
of experimental design; seven of the ten test set compounds have structural features not 
explicit in the training set. With this in mind statistical experimental design techniques 
[21,22] have been applied to these structures as described below. It is legitimate to make 
quite precise predictions of the steroid binding affinities − a lower bound to the SE of ~0.08 
(equivalent to r2 > 0.995) has previously been estimated [2]. 
Melatonin. The melatonin receptor ligands (Table 2 and Figure 4) consist of a TG of 44 
structures and a test set of 9 structures taken from a 3D-QSAR investigation by Sicsic et al. 
[20]. This TG (analysis "J" in Ref. 20) provided the best CoMFA model selected from a 
range of different TGs having up to 48 compounds and should thus provide a stringent test 
of the relative performance of EVA/EVA_GA. The TG ("T" name prefix in Table 2) 
consists of five classes of structure, including 9 indole, 21 naphthalene, 2 tricyclic, 2 
tetraline and 10 benzene-based compounds. The test set ("Z" name prefix) consists of 9 
compounds, 7 of which belong to the benzene, naphthalene or tricyclic classes and which to 
some extent reproduce structural features present in the TG. However, there are no explicit 
TG examples of the m-ethoxy substituents of the test compounds Z55 and Z56, one of the 
test set compounds is a quinolinic structure (Z49) and compound (Z50) is structurally 
related to one of the naphthalene compounds. There are, therefore, four test set compounds 
which a priori might be expected to (but need not necessarily) provide predictive problems 
for a QSAR model. 
Both the TG and test set compounds exhibit binding affinities (pKi) covering five orders of 
magnitude for chicken brain melatonin receptors (Table 2). The 44 TG compounds 
thoroughly and regularly span activity space (Figure 5). However, two of the test set 
compounds (Z49 and Z56) have lower activity than any of the 44 TG structures while only 
one of the TG compounds (T04) is less active than Z54. Not only is Z56 the least active 
compound overall but there is a gap of ~0.54 pKi units between it and the least active TG 
compound (T04), a much larger distance than exists elsewhere in "activity space". There is 
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once again, therefore, an expectation that there are likely to be predictive difficulties 
particularly with compound Z56 and, possibly, Z49. In the original CoMFA study [20] 
structure T47 has lower activity than Z56 but was excluded from the best CoMFA analysis 
since it was considered an outlier, a not unreasonable finding given that its pKi is ~0.6 units 
lower than that of T04. 
Calculation of Normal Mode Frequencies (EVA) 
Semiempirical. The steroid dataset was treated using the AM1 Hamiltonian of MOPAC 6.0 
[23] with the parameters described previously [3]. The conformations used for the CoMFA 
analyses were adopted as the starting points for the MOPAC geometry optimisation of all 
structures. None of the 31 structures had imaginary ("negative") normal mode frequencies, 
indicating that the optimized geometries were at or very close to a stationary point 
MM3 Molecular Mechanics. The melatonin ligands were geometry minimised using 
MM3(94) [24] molecular mechanics. As with the steroids, CoMFA conformations [20] were 
used as the starting points for the MM3 runs. The MM3 FULL_MATRIX option is required 
for a FORCE calculation to be done; all other MM3 parameters were left at their default 
values. Eleven of the structures had one imaginary NMF but the most negative of these was 
only -28.9 cm-1. The calculations are in any case unreliable from -50 cm-1 to 50 cm-1 so 
NMFs within this range are not significant; imaginary NMFs are excluded from 
consideration when generating the EVA descriptor. 
CoMFA Analyses 
For both datasets CoMFA analyses were performed so as to provide benchmark values 
against which to judge the performance of EVA/EVA_GA. The steroid CoMFA analysis 
has been described in some detail previously [3]; the structures and conformations are those 
of Wagener et al. [19] and were aligned using an RMS fit of the 3, 5, 6, 13, 14 and 17 
skeletal carbon atoms (Figure 6) with deoxycortisol (H11) as a template. For the melatonin 
ligands the superposed conformations were obtained directly from the original authors [20]. 
Most of the melatonin ligands have a highly flexible ethylamido side-chain (Figure 4) so the 
CoMFA alignments are based upon atom-based RMS fitting to the restrained tricyclic 
compounds (T33 and T34) using the alignment centres defined in that Figure. 
CoMFA was undertaken using a 1 Å grid-spacing rather than the default 2 Å. There is 
considerable evidence to suggest that results with the latter spacing are likely to be 
unreliable [8] and, therefore, the CVR2-GRS (Crossvalidated-r2-Guided Region Selection) 
method [8] − an unsophisticated domain-based variable selection procedure − was applied to 
the analyses. In addition, the robustness of the models was assessed at both 2 and 1 Å grid-
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spacing through reorientation tests, in which all compounds are reoriented as an aggregate 
rigid body within the bounding CoMFA 3D grid. This was done systematically, at fixed 
intervals of either 1° and 10° through 360° in each plane separately and in various 
combinations, and training and test set modelling and prediction performed for each 
orientation; this provides a means of estimating the stability and true statistical performance 
of the CoMFA PLS models. Evaluations such as this incorporating test set predictions have 
not been previously published. 
Aside from the grid resolution all other CoMFA parameters were kept at the Sybyl default 
values. MOPAC 6.0 AM1 [23] charges were used for the steroid analysis while Sybyl [9] 
Gasteiger and Marsili charges were utilised with the melatonin receptor ligands per the 
original publication [20]. As with the EVA analyses LOO or LNO (steroids only) CV was 
used with a maximum of M/4 LVs depending on the dataset size. Analyses were done using 
steric and electrostatic fields combined and were performed for unscaled and blockscaled 
data. Sybyl PLS was used for CoMFA regression analysis and models were selected on the 
basis of the SECV_MIN rule noted above.  
Results and Discussion 
Steroid Dataset 
CoMFA and EVA. As stated above the chosen steroid dataset previously has been 
investigated in some detail using both EVA and CoMFA [3] and only brief comments will 
be made here. With EVA the best models with fixed σ were obtained where σ = 3/4 cm-1 
(Table 3). These models had a q2 of 0.80 (two LVs) and a pr2 of 0.69 or 0.76 (excluding an 
outlier (M31) with a fluorine substituent not explicit in the TG). Test set predictions for σ 
values other than 3/4 cm-1 rapidly become very poor (Figure 7) so there is a quite distinct, 
limited range of optimal fixed σ for this dataset. The melatonin dataset on the other hand 
has a much broader (contiguous) band of σ values over which pr2 scores are relatively stable 
(see below). CoMFA modelling with this steroid dataset (Table 3) provides a very high q2 
score of 0.87 (two LVs) and an equally high test set pr2 (0.84) where the fluorine outlier is 
excluded. However, the CoMFA model is extremely sensitive to M31 and, when it is 
included in the test set, the pr2 score drops to 0.45. It has been suggested that this difference 
between CoMFA and EVA reflects the different information content of the vibrational and 
field-based descriptors. It is therefore of interest to determine whether or not optimisation of 
the EVA model using EVA_GA alters the sensitivity of the method to M31. It should also 
be noted that with a 1 Å CoMFA grid-spacing the PLS scores are quite stable under 
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aggregate reorientation [3]  the test pr2 scores show the greatest variation, ranging from 
0.42 to 0.48 (all compounds) and 0.81 to 0.86 (M31 excluded). 
EVA_GA  To start with the default GA parameters noted above were used together with R 
= {1, 2, 3, 4, 5} and LVmax = 2 both chosen according to EVA results (Figure 7, Table 3). 
However, a wide variety of alternatives parameters were investigated also (Tables 4−7). The 
most obvious feature of most of the results obtained is that it is possible to enhance q2 by up 
to 0.08 units (LOO CV) and 0.06 units (LNO CV) relative to the best EVA model (Table 3). 
The best predictive results are obtained where two or more LVs are available to EVA_GA 
and in general, but not exclusively, two LVs are optimal for both TG and test set 
predictions. Where two or more LVs are available test set pr2 scores (0.70-0.75) are virtually 
identical or slightly smaller than that obtained with EVA. Again, provided at least two LVs 
are available, EVA_GA is not sensitive to the PLS model selection criteria and there is 
nothing to be gained from setting MAX_CYCLES > 100 (Table 5) although, where 
MAX_CYCLES = 50 the results over five runs of the GA show considerable variation. In 
addition EVA_GA is not sensitive to the alternative values of NBINS that were investigated 
(Table 6).  
EVA_GA appears to be most sensitive to the choice of R set values (Table 7). For example, 
if relatively large σ such as 20 and 30 cm-1 are made available to the GA then, whether one, 
two or three LVs are used, LOO q2 is enhanced (to 0.82. 0.86 and 0.90 respectively) while 
pr2 scores are very poor where either M31 is included (0.47, 0.39 and 0.25) or excluded 
(0.59, 0.52 and 0.42); LNO-based searches provide only slightly better results in some 
cases. This is a similar finding to that with EVA where pr2 scores (and TG CV scores) are 
poorer where σ is not very close to 4 cm-1 (Figure 4). Examination of the Vopt solutions for 
each of the five GA runs indicates that large σ are incorporated into the solutions when 
made available. Random permutation tests applied to two sets of results where R = {1, 2, 3, 
4, 5} and {4, 8, 10, 20, 30} and where LVmax is two (Table 7 footnotes) indicate that (for 
LOO q2) in the latter case the estimated probability of chance correlation (p) is 0.021 for 
LV1 (i.e., greater than 1%) and 0.0005 for LV2 (mean p over 5 GA runs) while in the 
former case p is 0.0007 or 0.0006 for one or two LVs respectively. Thus, it seems that the 
possibility for chance correlation is greatly increased where large σ are used. Where the 
fitted-r2 is considered, in all cases p < 2.7 × 10-13. Thus, even in the absence of the poor test 
set predictions where R = {4, 8, 10, 20, 30}, the models based on the R set with smaller σ 
would be favoured for predictive purposes. 
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As noted above the steroid dataset lacks any sort of experimental design, statistical or 
otherwise, and in view of this the dataset as a whole was re-examined using PCA and PLS. 
It is acknowledged, however, that implicit in EVA_GA are changes to the descriptor space 
and that experimental design can be properly applied only where descriptor space is 
constant. However, we proceed on the assumption that some sort of design consideration is 
better than none at all. As an initial step PLS CV was applied to all 31 structures (σ = 4 cm-
1) giving a q2 of 0.75 (two LVs) against which the scores from subsequent designed models 
can be compared; note that a total of 21.9% of the X block (i.e., EVA descriptor) variance is 
explained by these two LVs. A PCA (no scaling) was then applied to the 31-compound X 
matrix. However, 19 PCs are required to explain 90% of the variance in X∗ with the first 
seven PCs explaining (cumulatively) 15.1%, 25.4%, 34.5%, 41.8%, 47.5 %, 52.8% and 
57.8% respectively − additional PCs explain < 5% further variance. The number of design 
points (compounds) required for a two-level factorial design (FD) with k variables (here, 
significant PCs) is 2k and that for a fractional FD (FFD) is 2k-1 (ignoring centre-points). Thus 
even where k = 7 and a two-level FFD is applied there is a requirement for a minimum of 64 
compounds. This is in any case an unsatisfactory summary of the univariate variance in X 
since 42.2% is left unexplained where only 7 PCs are considered. Therefore, further analysis 
was done so as to eliminate compounds that might be considered outliers: this can be done 
either in terms of the X space alone or in both X and Y space combined. Outliers in X space 
can be identified using Hotelling's T2, a multivariate generalisation of Student's t-test, which 
provides an elliptical confidence region for the data when viewed as two-dimensional score 
plots. Using 0.01 as a confidence limit, and through examination of all score plot 
combinations up to 7, 19 (90 % of X explained) and 30 (100 % of X explained to three d.p.) 
PCs, then 0 compounds, 4 compounds (M1, L16, M27 and M31) and 10 compounds 
(previous four plus: H7, L13, H19, H20, M21, M24) respectively can be considered 
significant outliers. When these compounds are excluded and PCA repeated 16 or 14 PCs 
respectively are required to explain 90% of the variance in the reduced descriptor blocks. 
Even with a 0.05 confidence limit for T2, using which threshold 21 compounds can be 
excluded, 7 PCs are required to explain 90% of the variance in X for the remaining 10 
compounds; clearly too many design variables where only 10 compounds are available. 
Thus, even where the chemical justification for excluding compounds is ignored, it seems to 
be the case that experimental design in PC space is difficult if not impossible with these 
compounds and this descriptor. 
In consequence of the difficulty of performing a PCA-based design it was decided to do a 
design in the PLS LV space which focuses attention upon the variance in X that is related to 
                                                          
∗ An equally large number of PCs is required to summarise the X matrix for the 53 melatonin ligands. 
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Y and is, therefore, a supervised or biased design. As noted above LOO CV using all 31 
compounds provides LOO/LNO q2 scores of 0.75 / 0.74 (2 LVs) − an additional LV does 
not improve q2 any further. Clearly, a FD with only two significant variables requires only 
four data points. However, ten data points is generally considered to be the minimum 
required for PLS analysis and, therefore, further compounds were selected, including centre-
points, so as to span the LV space thoroughly, giving a new TG consisting of L4, H6, H7, 
L9, L13, L18, H22, H23, M26, M27 and H30 (DESIGN_A). EVA analysis (Table 8) 
provided an optimal model where σ = 4 cm-1 with LOO/LNO q2 scores of 0.55 / 0.54 (one 
LV) − which are somewhat less than all-compound CV − with an r2 of 0.89 and a pr2 of 0.51 
(or 0.55 excluding M31). It is to be expected that CV using a sparse, designed set of 
compounds give a lower q2 relative to instances where there is much redundancy. 
Application of EVA_GA to DESIGN_1 (Table 8) provided enhanced q2 and r2 scores (0.71 
and 0.96 respectively) while the pr2 score was, once again, not significantly altered whether 
or not M31 is included in the test set. 
A second design was made (DESIGN_B) but this time the three largest outliers from all-
compound CV (H22, M27, H31) were excluded entirely. With EVA this set of 28 
compounds provided optimal LOO/LNO q2 scores of 0.84 / 0.83 (2 LVs) where σ = 4 cm-1. 
Ten compounds were picked from an LV score plot as before (Table 8) which provided an 
EVA model with LOO/LNO q2 scores of 0.69 / 0.66 (2 LVs) and a pr2 of 0.69; that is, both 
predictive scores are reasonably high and their values very similar indicating that here q2 is 
good indication of model predictivity. The application of EVA_GA (Table 8) provided 
enhanced q2 scores (0.81 with 2 LVs) and a slightly reduced pr2 score (0.66, whether M31 is 
included or not). Thus, overall it appears that there is nothing to be gained or lost in terms of 
test compound predictivity through the application of EVA_GA with the various steroid 
training / test sets evaluated. 
Melatonin Receptor Ligands 
CoMFA Results. A CoMFA was performed using a set of aligned structures obtained 
directly from Sicsic et al. [20]; note that for reasons discussed above dataset "J" was 
selected from that paper. The results of our CoMFA are listed in Table 9 together with those 
obtained by the original authors. It is apparent that our results differ somewhat from those of 
Sicsic et al. despite ensuring as far as possible that the CoMFA parameters were identical. 
The reason for this is most likely that, as noted above [8], a 2 Å grid resolution usually adds 
a sampling error into the descriptors in as much as the results obtained depend upon the 
orientation of the structures as an aggregate body relative to the 3D grid. For this reason a 1 
Å resolution has been recommended [8] since it is said to provide relatively orientation-
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independent results. Indeed, the mean PLS scores (q2, r2, pr2) of ~3,800 reorientations of the 
aggregate using a 2 Å resolution are almost identical to the single orientation 1 Å results 
(Table 9); this also applies where mean values from the same set of reorientations are 
assessed at a 1 Å grid-spacing. The range of PLS scores obtained is extremely wide at 2 Å, 
particularly for the test set predictions ( >0.4 units), and the scores obtained by Sicsic et al. 
certainly fall within these limits. At a 1 Å resolution the PLS scores are more stable 
covering ~0.1 units for q2 and r2 while pr2 scores again show the greatest variance ranging 
from 0.66 to 0.80 for all nine compounds and from 0.53 to 0.76 where Z55 and Z56 are 
excluded. What is more there is only a very low correlation between q2 and pr2 (r = 0.15) so 
choosing a suitable orientation on the basis of CV scores provides no indication as to what 
the true pr2 may be. Overall, these results indicate that a 2 Å resolution is inadequate with 
this dataset and that test set scores can show significant variation even at a 1 Å resolution. 
EVA Results. A large number of EVA descriptor sets derived using a range of different 
fixed Gaussian σ were evaluated on the basis of training and test set statistics. It is clear 
from the LOO CV results (Figure 8) that the best training set models are those where σ = 
3−15 cm-1, depending upon which LVs are considered. LV1 is maximal where σ < ~4 cm-1, 
while the addition of LV2 and subsequent LVs results in progressively higher peaks where 
σ ≈ 10 cm-1. Thus, where σ = 10 cm-1 (Table 10), if the 5%_RULE is applied q2 is 0.46 (2 
LVs), while a model based on SECV_MIN has a q2 of 0.53 (5 LVs). If MAX_Q2 is the 
selection criterion then q2 = 0.58 (8 LVs); this is in fact the highest observed q2 for all 
models where a maximum of ten LVs are extracted. Thus, whatever criterion is used to 
select LVopt, and thence the optimal σ to use, q2 is not particularly high. Test set predictions 
where σ = 10 cm-1 are, on the other hand, somewhat better (Table 10) with the parsimonious 
models providing the best pr2 scores of 0.66 for all nine compounds and ~0.81 (2 or 5 LVs) 
if the previously noted outliers (Z55/Z56) are excluded. Overall, with this data set, and in 
contrast to the steroid results, the selection of LVopt and the best fixed σ is not clear cut. In 
comparison to CoMFA these EVA results are poorer, particularly where q2 is considered 
while there are much smaller differences in pr2 scores. The EVA predictions are quite 
sensitive to the presence of compounds Z55 and Z56 (~0.15 units difference) while this is 
less the case for CoMFA − 0.06 units difference where the mean values of aggregate 
reorientation at 1 Å resolution are considered (Table 9). 
EVA_GA. As previously, an initial R set was chosen based upon σ values centred around 
the optimal EVA training set σ of 10 cm-1 (Figure 8); thus, R1 = {3, 5, 8, 10, 12}. These 
results also suggest that LVmax should be two or three; the larger value was chosen since this 
permits the GA to select either dimensionality. However, the effect, if any, of alternative 
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choices of parameters are considered below. The PLS_MODEL_SELECTION method was 
the 5%_RULE since this provides the most straightforward selection of LVopt from the 
optimal solutions produced by the GA.  
If the results where R = R1, as suggested by the EVA results, are considered (Table 11) it is 
apparent that it is always the cases that solutions can be obtained with EVA_GA that have 
substantially higher q2 than EVA. It is also the case that this improvement does not require 
additional LVs. Indeed, the one-LV EVA_GA models have roughly the same LOO/LNO q2 
(~0.58/~0.53) as the eight-LV EVA model (Table 10) and test set predictivity that is equal 
to that of the optimal EVA models (pr2 = ~0.65 or ~0.80, including and excluding Z55/Z56 
respectively). If further LVs are made available to the GA then it is clear that two or three 
LV models provide the best test set scores (~0.75 / ~0.88) representing worthwhile 
improvements over the EVA scores. Even where five LVs are made available to the GA, 
LVopt is indicated to be two or three provided that the more conservative LNO CV is used 
for fitness scoring during population evolution. The use of LOO CV for fitness scoring 
where LVmax > 3 produces the highest q2 scores (up to 0.70 with LVopt = 4 or 5) but the 
models begin to show signs of overfit to the TG (pr2 = ~0.58 / ~0.79). If an alternative R set 
is considered (R2 = {2, 4, 6, 8, 10}) the results (Table 11) are almost identical to those with 
R1 as might be expected, the only substantive difference being the better pr2 scores where 
LVmax = 5. If very much larger σ are made available to the GA (R3 = {5, 10, 15, 20, 30}) q2 
scores can be enhanced to similar levels as with R1 and R2 while their is little or no 
improvement in pr2 scores relative to EVA where LVmax > 1. Where only one LV is 
available q2 and test set scores are poorer than when more LVs are available as was found 
also with sets R1 and R2. The findings with R3 suggest that lower σ help to limit the 
possibilities for TG overfit − this was even more strongly indicated with the steroid results 
(Table 7). In any case the EVA results over a range of fixed σ (Figure 8) suggest that the use 
of large σ would not be useful. Note that none of the models listed (Table 11) are 
contraindicated by random permutation tests at any number of LVs. 
Thus far the results described have been with default EVA_GA settings and a variety of R 
sets and LVmax. The results with alternative MAX_CYCLES (Table 12) suggest that 100 
cycles is certainly adequate, where the other parameters are their default values, and there is 
clearly little or nothing to be gained from using more than 100 GA iterations. Where only 50 
iterations are available the mean score values (over five GA runs) are similar to those where 
more runs are used but, as with the steroids, there is much greater variation in the scores 
over the five runs and 100 iterations is preferred. Where alternative bin widths are 
considered (Table 13) the best results in terms of prediction are obtained where NBINS is 
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100 or 200 while poorer scores are obtained where NBINS ≥ 400 despite the improvements 
to q2. However, even where NBINS = 800 (~5425 available permutations where empty bins 
are excluded) and MAX_CYCLES = 1,000 (Table 13) test set predictions remain at least as 
good as those with EVA (Table 10).  
Conclusion 
A method has been described that explores an alternative formulation of the EVA QSAR 
technique (EVA_GA) incorporating the localisation of the values of the main EVA 
parameter, the Gaussian kernel width (σ). A genetic algorithm has been used to explore 
localised "σ space" using the scores from LOO or LNO PLS crossvalidation as the fitness to 
be maximised by the GA. When applied to a benchmark steroid dataset, for which really 
quite good results had already been obtained using classical EVA, the EVA_GA could 
always find improved training set models but for the most part test set predictivity was 
improved not at all. However, except with certain parameter choices (availability of high σ) 
contraindicated by both the classical EVA results and random permutation tests, test set 
predictivity was as good as that with EVA. Similar results were obtained where the training 
/ test division of structures was modified using statistical experimental design criteria.  
With a second relatively heterogeneous set of melatonin receptor ligands, representing five 
structural classes, the results obtained were much more encouraging. Again, it was always 
found that higher q2 scores (typically, up to 0.25 units better) could be obtained with 
EVA_GA compared to fixed σ EVA. However, in contrast to the steroid results, test set 
predictive scores were also substantially enhanced in most cases. As with the steroid set the 
availability (and incorporation by EVA_GA into optimal solutions) of σ values larger than 
those suggested by the EVA results leads to indications of training set overfit. Where large 
numbers of latent variables are made available to EVA_GA the possibilities for overfit 
increase although, with this melatonin dataset, the use of the more conservative LNO PLS 
crossvalidation helps to control model dimensionality such that this avoided. 
Overall, additional work is needed so as to verify that EVA_GA is an effective technique, to 
attempt to generalise these findings into a set of parameters that might be expected to be 
widely applicable, and to examine the obtained models in detail so as to look at what 
changes are being made by EVA_GA in descriptor space. Further development of EVA_GA 
might include the incorporation of some limited form of random permutation testing into the 
chromosome scoring function, perhaps simply to reject a chromosome entirely if it fails to 
meet certain criteria. Also being considered is combination of the method described with 
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more standard variable selection procedures in which variables may be removed from 
consideration entirely; i.e., permit σ to be zero. 
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Figure Captions 
Fig. 1.  Histogram summarising the number of fundamental NMFs found in different regions of the 
IR spectrum (melatonin receptor ligand training dataset, bin widths (w) of 40 cm-1). 
Fig. 2.  Example of the different kernel widths and shapes obtained after expansion with selected 
Gaussian standard deviation (σ) values (after scaling to unit maximum amplitude) for a single 
hypothetical frequency at 29 cm-1. 
Fig. 3.  Overview of GA routine. 
Fig. 4.  Melatonin training and test set compounds with CoMFA superposition centresa. 
Fig. 5.  Distribution of melatonin receptor ligands in activity space.  
Fig. 6. Steroid skeleton. 
Fig. 7. Steroid dataset: cumulative q2 for successive PLS LVs for classical EVA models derived from 
a range of σ values. 
Fig. 8.  Cumulative LOO q2 for successive PLS LVs for classical EVA models derived from a range 
of σ values: melatonin receptor ligands. 
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TABLE 1 
STEROID CBG-BINDING AFFINITIES 
__________________________________________________ 
 Compound CBG Affinity 
Training Set log [K] 
M1  Aldosterone 6.279 
L2  Androstanediol  5.000 
L3  Androstenediol 5.000 
L4  Androstenedione 5.763 
L5  Androsterone 5.613 
H6  Corticosterone 7.881 
H7  Cortisol 7.881 
M8  Cortisone 6.892 
L9   Dehydroepiandrosterone 5.000 
H10 Deoxycorticosterone 7.653 
H11 Deoxycortisol 7.881 
M12 Dihydrotestosterone 5.919 
L13 Estradiol 5.000 
L14 Estriol 5.000 
L15 Estrone 5.000 
L16 Etiocholanolone 5.255 
L17 Pregnenolone 5.255 
L18 17-Hydroxypregnenolone 5.000 
H19 Progesterone 7.380 
H20 17-Hydroxyprogesterone 7.740 
M21 Testosterone 6.724 
Test Set 
H22 Prednisolone 7.512 
H23 Cortisol 21-acetate 7.553 
M24 4-Pregnene-3,11,20-trione 6.779 
H25 Epicorticosterone 7.200 
M26 19-Nortestosterone 6.144 
M27 16α,17-Dihydroxy-4-pregnene-3,20-dione 6.247 
H28 17-Methyl-4-pregnene-3,20-dione 7.120 
M29 19-Norprogesterone 6.817 
H30 11β,17,21-Trihydroxy-2α-methyl- 
                             4-pregnene-3,20-dione 7.688 
M31 11β,17,21-Trihydroxy-2α-methyl- 
            9α-fluoro-4-pregnene-3,20-dione 5.797 
__________________________________________________ 
Structure numbers and activity group classification prefixes (but not the 
structures themselves) are those used by Good et al. [25]: H - high 
activity; M - medium; L - low. 
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TABLE 2 
MELATONIN RECEPTOR LIGANDS BINDING AFFINITIESa
name pKi  name pKi  name pKi  name pKi  name pKi 
T01 9.17  T12 10.62  T25 8.66  T36 6.67  Z49 6.23 
T02 10.49  T13 9.92  T26 7.71  T37 6.67  Z50 8.59 
T03 6.80  T15 7.52  T27 9.26  T38 6.71  Z51 10.30 
T04 6.31  T16 8.03  T28 8.45  T39 6.94  Z52 8.85 
T05 9.85  T17 6.49  T29 8.23  T40 6.66  Z53 7.77 
T06 8.60  T19 9.62  T30 8.97  T41 6.64  Z54 6.41 
T07 8.60  T20 10.14  T31 7.92  T42 7.19  Z55 6.83 
T08 8.17  T21 9.41  T32 7.25  T43 7.15  Z56 5.77 
T09 7.66  T22 8.77  T33 7.46  T44 7.38  Z57 7.09 
T10 9.27  T23 8.57  T34 8.22  T45 6.54    
T11 9.74  T24 9.17  T35 6.69  T46 6.60    
a Binding affinities for chicken brain melatonin receptors [20]. Training set compounds are prefixed by "T" while test set 
compounds are prefixed by "Z". 
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TABLE 3 
CLASSICAL EVA AND COMFA PLS STATISTICS: STEROID DATASET 
    CV    Fitted Model  Test Set pr2
Analysis Parameters LVopt
q2 
LOO / LNOa
SECV  
LOO / LNOa p
b r2 SE pb
With/Without 
M31 
M31 
residual 
"Classical" EVA σ = 4 cm-1 2 0.80 / 0.79 0.55 / 0.57 0.001 0.96 0.24 0.0029 0.69 (0.74) +0.67 
CoMFA See main text 2 0.87 / 0.84 0.45 / 0.49 0.0001 0.93 0.32 0.00002 0.45 (0.84) +1.91 
a Mean of 200 runs of LNO CV where G = 7. 
b For both LOO q2 and fitted r2, p is an estimate of the probability of chance correlation based upon 1,000 random 
permutations of Y. 
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TABLE 4 
EVA_GA PLS RESULTS: STEROID DATASET 
   GA Parametersa      CVb   Fitb Test Set b
RULEc LVmax CV RULEd LVopt q2 SECV r2
pr2
All / No M31 
5%_RULE 3 LOO BOTH 2 0.84 0.49 0.98 0.68 / 0.72 
  LNO BOTH 2 0.82 0.53 0.98 0.66 / 0.70 
 2 LOO BOTH 2 0.86 0.47 0.98 0.68 / 0.73 
  LNO BOTH 2 0.84 0.50 0.98 0.67 / 0.71 
 1 LOO BOTH 1 0.83 0.50 0.96 0.65 / 0.70 
  LNO BOTH 1 0.80 0.53 0.95 0.65 / 0.70 
SECV_MIN 3 LOO SECV_MIN 2e 0.86 0.47 0.99 0.68 / 0.74 
   5%_RULE 1f 0.83 0.51 0.96 0.67 / 0.71 
  LNO SECV_MIN 2 0.83 0.51 0.98 0.65 / 0.71 
   5%_RULE 1 0.80 0.53 0.96 0.63 / 0.68 
 2 LOO SECV_MIN 2 0.86 0.47 0.99 0.64 / 0.70 
   5%_RULE 1 0.83 0.50 0.97 0.63 / 0.68 
  LNO SECV_MIN 2 0.83 0.51 0.98 0.63 / 0.68 
   5%_RULE 1 0.80 0.54 0.96 0.62 / 0.65 
MAX_Q2 3 LOO SECV_MIN 3f 0.86 0.48 0.99 0.63 / 0.69 
   5%_RULE 1 0.80 0.53 0.96 0.62 / 0.66 
  LNO SECV_MIN 2 0.82 0.52 0.98 0.65 / 0.70 
   5%_RULE 1 0.79 0.55 0.95 0.62 / 0.66 
 2 LOO SECV_MIN 2 0.86 0.46 0.98 0.65 / 0.71 
   5%_RULE 1 0.83 0.49 0.96 0.63 / 0.68 
  LNO SECV_MIN 2 0.82 0.52 0.98 0.66 / 0.71 
   5%_RULE 1 0.79 0.54 0.96 0.64 / 0.69 
a Default GA parameters unless otherwise stated; R = {1, 2, 3, 4, 5}. 
b All PLS statistics are for descriptors derived from Vopt and are mean values taken from 5 GA runs. 
c Rule used to select LVopt and thus the chromosome fitness score (q2) during evolution of the GA. 
d Rule used to select LVopt and thus the final PLS statistics for Vopt.as distinct from c. 
e LVopt = 3 for 2 runs. 
f LVopt = 2 for one of the five runs. 
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TABLE 5 
EVA_GA PLS RESULTS: STEROID DATASET: EFFECT OF MAX_CYCLESa
  GA Parameters     CV   Fit Test Set 
MAX_CYCLESb LVmax CV LVopt q2 SECV r2
pr2
All / No M31 
50 2 LOO 2 0.84 0.50 0.97 0.66 / 0.70 
100 2 LOO 2 0.86 0.47 0.98 0.68 / 0.73 
200 2 LOO 2 0.87 0.46 0.98 0.66 / 0.70 
400 2 LOO 2 0.85 0.48 0.98 0.69 / 0.73 
1000 2 LOO 2 0.87 0.45 0.98 0.67 / 0.72 
a See footnotes to Table 4 for further information; R = {1, 2, 3, 4, 5}. 
b Maximum iterations of the GA - each run was started separately with a 
different random seed and CONV_CRIT set so that convergence was not 
reached in any run. 
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TABLE 6 
EVA_GA PLS RESULTS: STEROID DATASET: ALTERNATIVE BIN WIDTHSa
   GA Parameters      CV   Fit Test Set 
NBINS w LVmax CV LVopt q2 SECV r2
pr2
All / No M31 
50  80 cm-1 2 LOO 2 0.83 0.51 0.97 0.68 / 0.73 
   LNO 2 0.80 0.55 0.97 0.65 / 0.69 
100 40 cm-1 2 LOO 2 0.86 0.47 0.98 0.68 / 0.73 
   LNO 2 0.84 0.50 0.98 0.67 / 0.71 
200 20 cm-1 2 LOO 2 0.85 0.48 0.98 0.63 / 0.69 
   LNO 2 0.82 0.52 0.98 0.67 / 0.71 
400 10 cm-1 2 LOO 2 0.86 0.46 0.99 0.65 / 0.72 
   LNO 2 0.83 0.51 0.98 0.67 / 0.74 
400b 10 cm-1 2 LOO 2 0.88 0.44 0.98 0.69 / 0.75 
   LNO 2 0.85 0.49 0.98 0.66 / 0.72 
800c 5 cm-1 2 LOO 2 0.89 0.41 0.99 0.66 / 0.73 
   LNO 2 0.85 0.48 0.98 0.69 / 0.75 
a See footnotes to Table 4 for further information; R = {1, 2, 3, 4, 5}. 
b MAX_CYCLES = 400. 
c MAX_CYCLES = 500. All model converged prior to MAX_CYCLES of the GA. 
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TABLE 7 
EVA_GA PLS RESULTS: STEROID DATASET: ALTERNATIVE R SETSa
   GA Parameters      CV   Fit Test Set 
R LVmax CV LVopt q2 SECV r2
pr2
All / No M31 
{1, 2, 3, 4, 5} 2 LOO 2 0.86b 0.47 0.98c 0.68 / 0.73 
  LNO 2 0.84 0.50 0.98 0.67 / 0.71 
{2, 3, 4, 5, 6} 2 LOO 2 0.84 0.50 0.97 0.67 / 0.72 
  LNO 2 0.81 0.54 0.97 0.66 / 0.71 
{2, 3, 4} 2 LOO 2 0.79 0.57 0.97 0.68 / 0.73 
  LNO 2 0.79 0.57 0.98 0.68 / 0.72 
 1 LOO 1 0.76 0.59 0.95 0.62 / 0.68 
  LNO 1 0.77 0.57 0.95 0.64 / 0.69 
{3, 4, 5, 8, 10} 3 LOO 2 0.85 0.47 0.97 0.61 / 0.65 
  LNO 2 0.83 0.51 0.96 0.65 / 0.70 
 2 LOO 2 0.86 0.47 0.97 0.64 / 0.68 
  LNO 2 0.83 0.51 0.97 0.62 / 0.66 
 1 LOO 1 0.79 0.54 0.93 0.62 / 0.68 
  LNO 1 0.79 0.55 0.93 0.61 / 0.68 
{4, 8, 10, 20, 30} 3 LOO 3 0.90 0.40 0.98 0.25 / 0.42 
  LNO 3 0.87 0.45 0.98 0.27 / 0.41 
 2 LOO 2 0.86d 0.45 0.95e 0.39 / 0.52 
  LNO 2 0.85 0.48 0.95 0.45 / 0.60 
 1 LOO 1 0.82 0.51 0.91 0.47 / 0.59 
  LNO 1 0.80 0.54 0.91 0.49 / 0.59 
a See footnotes to Table 4 for further information. 
b Chance correlation estimates, p, for q2 are 0.0007 (LV1)  and 0.0006 (LV2) 
(mean values for the five GA runs). 
c Chance correlation estimates, p, for r2 are 0 (LV1 and LV2). 
d Chance correlation estimates, p, for q2 are 0.021 (LV1) and 0.0005 (LV2). 
e Chance correlation estimates, p, for r2 are 2.7 × 10-13 (LV1) and 0 (LV2). 
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TABLE 8 
STEROIDS: ALTERNATIVE TRAINING AND TEST SET DESIGNS 
 
   Classical EVA      EVA_GA1   
Design σopt LOO/LNO q2 LVopt r2 pr
2
All / No M31 LVmax LOO q
2 LVopt r2
pr2
All / No M31
Aa 4 cm-1 0.55 / 0.54 1 0.89 0.51 / 0.57 2 0.71 1 0.96 0.50 / 0.55 
Bb 4 cm-1 0.69 / 0.66 2 0.99 0.69 / 0.70 2 0.81 2 0.99 0.66 / 0.66 
1 Default GA parameters: models selected according to 5%_RULE; R = { 1, 2, 3, 4, 5}. 
a ALL 31 compounds retained: TG = {L4, H6, H7, L9, L13, L18, H22, H23, M26, M27, H30}; M = 11; 20 Test compounds. 
b H22, M27 and M31 excluded entirely: TG = {L4, H6, L9, H10, L13, L18, H23, M24, M26, H30}; M = 10; 18 Test compounds. 
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TABLE 9 
MELATONIN RECEPTOR LIGANDS: DETAILED COMFA PLS RESULTS. 
 
 CoMFA Settings   Training Set   Test Set pr2
Model Grid Resolution Scaling LOO CV q2 SECV Fitted r2 All Excl. Z55/56 
    Literature 2Å not known 0.80 (5)a 0.61 0.97 0.76 not known 
    Supplied 
2Å 
 
1Å 
None 
Block 
None 
Block 
0.65 (3) 
0.66 (3) 
0.69 (3)b 
0.64 (2) 
0.76 
0.75 
0.72 
0.76 
0.84 
0.88 
0.86c 
0.79 
0.68 
0.67 
0.72 
0.68 
0.67 
0.58 
0.71 
0.64 
    CVQ2-GRS [8] 
q2 cut-off = 0.1d
q2 cut-off = 0.3d
None 
None 
0.70 (3) 
0.67 (3) 
0.71 
0.74 
0.87 
0.84 
0.74 
0.72 
0.72 
0.65 
    Aggregate 2Å None 
0.58 − 0.81f
mean 0.69 ncg
0.72 − 0.97f
mean 0.87 
0.43 − 0.88f
mean 0.70 
0.13 − 0.88f
0.67 
    Reorientatione
1Å None 
0.67 − 0.76f
mean 0.72 ncg
0.85 − 0.97f
mean 0.93 
0.66 − 0.80f
mean 0.73 
0.53 − 0.76f
0.67 
a Model LVopt picked on the basis of the (coincident) largest q2 and smallest SECV [20]. 
b Random permutation: for LOO q2, p = 2.2 × 10-5.  c Random permutation: for fitted r2, p = 2.2 × 10-6. 
d Cut-off value for q2 using which sub-regions are excluded from the final CoMFA; a 1 Å grid resolution is used throughout. 
e See main text for details for reorientations used.  f Minimum and maximum observed values. 
g Mean and ranges for SECV not calculated. 
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TABLE 10 
CLASSICAL EVA PLS STATISTICS: MELATONIN DATASET 
   CV   Fitted Model Test Set pr2
Parameters RULE LVopt
q2 
LOO / LNOa
SECV  
LOO / LNOa p
b r2 SE pb All 
Excl. 
Z55/56 
σ = 10 cm-1 5%_RULE 2 0.46 / 0.44 0.93 / 0.95 0.0005 0.79 0.58 0.0e 0.66 0.81 
 SECV_MIN 5 0.54 /  c 0.90 /   c 0.0026 0.95 0.29 0.0e 0.66 0.82 
 MAX_Q2d 8 0.58 / 0.53 0.90 / 0.94 0.0043 0.98 0.19 0.0e 0.43 0.60 
a Mean of 200 runs of LNO CV where G = 7. 
b For both LOO q2 and fitted r2 p is an estimate of the probability of chance correlation based upon 1,000 random 
permutations of Y. 
c Two LVs were optimal using LNO CV. 
d This also corresponds to the overall q2 maximum where ten LVs are extracted. 
e Normalised Z > 23. 
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TABLE 11 
EVA_GA PLS RESULTS: MELATONIN DATASET: ALTERNATIVE R SETSa
  GA Parameters     CV   Fit Test Set 
R LVmax CV RULEb LVopt q2 SECV r2
pr2
All / No Z55/56
R1 = {3, 5, 8, 10, 12} 5 LOO SECV_MIN 5d 0.70 0.72 0.96 0.58 / 0.79 
   5%_RULE 4h 0.69 0.73 0.95 0.58 / 0.80 
  LNO SECV_MIN 2i 0.61 0.80 0.88 0.74 / 0.87 
   5%_RULE 2g 0.61 0.80 0.87 0.76 / 0.90 
 3 LOO BOTH 3j 0.65 0.76 0.90 0.72 / 0.89 
  LNO BOTH 2f 0.61 0.79 0.88 0.77 / 0.89 
 2 LOO BOTH 2 0.64 0.76 0.87 0.76 / 0.87 
  LNO BOTH 2 0.61 0.80 0.86 0.75 / 0.88 
 1 LOO n/a 1 0.58 0.82 0.75 0.65 / 0.83 
  LNO n/a 1 0.55 0.84 0.74 0.63 / 0.80 
R2 = {2, 4, 6, 8, 10} 5 LOO SECV_MIN 5c 0.70 0.72 0.98 0.63 / 0.80 
   5%_RULE 4d 0.69 0.73 0.95 0.66 / 0.83 
  LNO BOTH 2e 0.64 0.77 0.89 0.74 / 0.88 
 3 LOO BOTH 3d 0.67 0.74 0.92 0.76 / 0.89 
  LNO SECV_MIN 2f 0.62 0.79 0.89 0.72 / 0.86 
   5%_RULE 2g 0.61 0.79 0.88 0.73 / 0.86 
 2 LOO BOTH 2 0.65 0.76 0.88 0.74 / 0.87 
  LNO BOTH 2 0.63 0.78 0.87 0.74 / 0.86 
 1 LOO n/a 1 0.59 0.80 0.76 0.67 / 0.80 
  LNO n/a 1 0.58 0.81 0.76 0.65 / 0.78 
R3 = {5, 10, 15, 20, 30} 3 LOO BOTH 3 0.68 0.73 0.91 0.69 / 0.77 
  LNO BOTH 3 0.63 0.78 0.90 0.64 / 0.80 
 2 LOO BOTH 2 0.63 0.78 0.83 0.65 / 0.80 
  LNO BOTH 2 0.58 0.82 0.82 0.64 / 0.80 
 1 LOO n/a 1 0.55 0.85 0.70 0.50 / 0.74 
  LNO n/a 1 0.53 0.86 0.68 0.47 / 0.74 
a See footnotes to Table 4 for further information. 
b Rule used to select LVopt and thus the final PLS statistics for Vopt.− not an EVA_GA parameter. 
c For two solutions LVopt = 4. d For one solution LVopt = 2. e For one solution LVopt = 4. 
f For two solutions LVopt = 3. g For one solution LVopt = 3. 
h For one solution LVopt = 2; for one solution LVopt = 5.  i For one solution LVopt = 5. 
j For two solutions LVopt = 2. 
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TABLE 12 
EVA_GA PLS RESULTS: MELATONIN DATASET: EFFECT OF MAX_CYCLESa
  GA Parameters     CV   Fit Test Set 
MAX_CYCLESc LVmax CV LVopt q2 SECV r2
pr2
All / No Z55/56 
50 3 LOO 3c 0.64 0.77 0.90 0.74 / 0.89 
100 3 LOO 3c 0.65 0.76 0.90 0.72 / 0.89 
200 3 LOO 3c 0.67 0.74 0.91 0.74 / 0.90 
400 3 LOO 3 0.68 0.73 0.92 0.73 / 0.90 
1000 3 LOO 3 0.70 0.71 0.92 0.72 / 0.90 
a See footnotes to Table 4 for further information; R = {3, 5, 8, 10, 12}. 
b Maximum iterations of the GA − each run was started separately 
with a different random seed and the CONV_CRIT set so that 
convergence was not reached. 
c For one solution LVopt = 2. 
TABLE 13 
EVA_GA PLS RESULTS: MELATONIN DATASET: ALTERNATIVE BIN WIDTHSa
  GA Parameters     CV   Fit Test Set 
NBINS w LVmax CV LVopt q2 SECV r2
pr2
All / No Z55/56 
50  80 cm-1 3 LOO 3b 0.61 0.80 0.90 0.70 / 0.83 
100 40 cm-1 3 LOO 3c 0.65 0.76 0.90 0.72 / 0.89 
200 20 cm-1 3 LOO 3 0.71 0.70 0.95 0.72 / 0.88 
400 10 cm-1 3 LOO 3 0.75 0.65 0.96 0.73 / 0.81 
800 5 cm-1 3 LOO 3 0.80 0.58 0.98 0.68 / 0.86 
800d 5 cm-1 3 LOO 3 0.91 0.39 0.99 0.67 / 0.81 
a See footnotes to Table 4 for further information; R = {3, 5, 8, 10, 12}. 
b For one solution LVopt = 2.  c For two solutions LVopt = 2. 
d MAX_CYCLES = 1000; CONV_CRIT = 0.025. For three of the five 
EVA_GA runs the population converged (after between 965 and 972 cycles) 
while the other two runs were very close to convergence (both 0.039) at 
MAX_CYCLES. 
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Fig. 1.  Histogram summarising the number of fundamental NMFs 
found in different regions of the IR spectrum (melatonin receptor 
ligand training dataset, bin widths (w) of 40 cm-1). 
 
0 
50 
100 
150 
200 
250 
Wavenumber ranges (cm-1) 
Counts 
200 400 600 800 1000 1200 1400 1600 1800 2000 2200 2400 2600 2800 3000 3200 3400 3600 3800 4000 0 
???????????????? Skeletal region ????????????????  ??????? Functional Group ???????         ??????????? Hydrogen Stretch  ???????????? 
                                                                                                                             Region                Region 
 
 
 
 34
Fig. 2.  Example of the different kernel widths and shapes 
obtained after expansion with selected Gaussian standard 
deviation (σ) values (after scaling to unit maximum amplitude) 
for a single hypothetical frequency at 29 cm-1. 
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Fig. 3.  Overview of GA routine. 
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Fig. 4.  Melatonin training and test set compounds with CoMFA superposition centresa. 
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Fig. 5.  Distribution of melatonin receptor ligands in activity space.  
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Fig. 6. Steroid skeleton. 
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Fig. 7. Steroid dataset: cumulative q2 for successive PLS LVs for classical EVA models derived from 
a range of σ values. 
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Fig. 8.  Cumulative LOO q2 for successive PLS LVs for classical EVA 
models derived from a range of σ values: melatonin receptor ligands. 
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